Fundamental Analysis of 22ND CENTURY GROUP INC(NASDAQ:XXII) stock

Fundamental Rating

XXII gets a fundamental rating of 1 out of 10. The analysis compared the fundamentals against 10 industry peers in the Tobacco industry. XXII may be in some trouble as it scores bad on both profitability and health. XXII has a expensive valuation and it also scores bad on growth.

Quickly go to:

1. Profitability

1.1 Basic Checks

In the past year XXII has reported negative net income.

In the past year XXII has reported a negative cash flow from operations.

In the past 5 years XXII always reported negative net income.

XXII had a negative operating cash flow in each of the past 5 years.

1.2 Ratios

With a Return On Assets value of -956.76%, XXII is not doing good in the industry: 90.00% of the companies in the same industry are doing better.

		Industry Rank	Sector Rank
ROA	-956.76%
ROE	N/A
ROIC	N/A

ROA(3y)-214.41%

ROA(5y)-143.97%

ROE(3y)N/A

ROE(5y)N/A

ROIC(3y)N/A

ROIC(5y)N/A

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for XXII so they could not be analyzed.

		Industry Rank	Sector Rank
OM	N/A
PM (TTM)	N/A
GM	N/A

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3YN/A

GM growth 5YN/A

More info and screens

ROA

ROE

ROIC

Operating and Profit Margin

Show most profitable peers

2. Health

2.1 Basic Checks

XXII does not have a ROIC to compare to the WACC, probably because it is not profitable.

XXII has less shares outstanding than it did 1 year ago.

XXII has less shares outstanding than it did 5 years ago.

The debt/assets ratio for XXII is higher compared to a year ago.

2.2 Solvency

XXII has an Altman-Z score of -30.14. This is a bad value and indicates that XXII is not financially healthy and even has some risk of bankruptcy.

XXII has a Altman-Z score of -30.14. This is amonst the worse of the industry: XXII underperforms 80.00% of its industry peers.

		Industry Rank	Sector Rank
Debt/Equity	N/A
Debt/FCF	N/A
Altman-Z	-30.14

ROIC/WACCN/A

WACC6.62%

2.3 Liquidity

XXII has a Current Ratio of 0.65. This is a bad value and indicates that XXII is not financially healthy enough and could expect problems in meeting its short term obligations.

XXII has a Current ratio of 0.65. This is in the lower half of the industry: XXII underperforms 70.00% of its industry peers.

XXII has a Quick Ratio of 0.65. This is a bad value and indicates that XXII is not financially healthy enough and could expect problems in meeting its short term obligations.

XXII has a worse Quick ratio (0.48) than 70.00% of its industry peers.

		Industry Rank	Sector Rank
Current Ratio	0.65
Quick Ratio	0.48

More info and screens

WACC

Debt/Equity

How to determine the health of a company

Altman-Z score

Show peers with great health

3. Growth

3.1 Past

The earnings per share for XXII have decreased strongly by -2301.90% in the last year.

XXII shows a strong growth in Revenue. In the last year, the Revenue has grown by 53.58%.

The Revenue has been growing slightly by 4.03% on average over the past years.

EPS 1Y (TTM)-2301.9%

EPS 3YN/A

EPS 5YN/A

EPS growth Q2Q-922.22%

Revenue 1Y (TTM)53.58%

Revenue growth 3Y4.64%

Revenue growth 5Y4.03%

Revenue growth Q2Q67.64%

3.2 Future

The Earnings Per Share is expected to grow by 35.86% on average over the next years. This is a very strong growth

Based on estimates for the next years, XXII will show a very negative growth in Revenue. The Revenue will decrease by -34.43% on average per year.

EPS Next Y79.88%

EPS Next 2Y35.86%

EPS Next 3YN/A

EPS Next 5YN/A

Revenue Next Year-58.25%

Revenue Next 2Y-34.43%

Revenue Next 3YN/A

Revenue Next 5YN/A

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.

More info and screens

Find the best growth stocks

Show best growing peers

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for XXII. In the last year negative earnings were reported.

Also next year XXII is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A

4.2 Price Multiples

		Industry Rank	Sector Rank
P/FCF	N/A
EV/EBITDA	N/A

4.3 Compensation for Growth

A more expensive valuation may be justified as XXII's earnings are expected to grow with 35.86% in the coming years.

PEG (NY)N/A

PEG (5Y)N/A

EPS Next 2Y35.86%

EPS Next 3YN/A

More info and screens

Show best valued peers

5. Dividend

5.1 Amount

XXII does not give a dividend.

		Industry Rank	Sector Rank
Dividend Yield	N/A

More info and screens

Find the best dividend stocks

Show peers with best dividend

22ND CENTURY GROUP INC

NASDAQ:XXII (5/2/2024, 3:35:14 PM)

After market: 1.6894 +0.01 (+0.56%)

1.68

+0.03 (+1.82%)

Chartmill FA Rating

GICS SectorConsumer Staples

GICS IndustryGroupFood, Beverage & Tobacco

GICS IndustryTobacco

Earnings (Last)

Earnings (Next)

Inst Owners

Inst Owner Change

Ins Owners

Ins Owner Change

Market Cap9.41M

Analysts

Price Target

Dividend

		Industry Rank	Sector Rank
Dividend Yield	N/A

Dividend Growth(5Y)

Div Incr Years

Div Non Decr Years

Ex-Date

Surprises & Revisions

EPS beat(2)

Avg EPS beat(2)

Min EPS beat(2)

Max EPS beat(2)

EPS beat(4)

Avg EPS beat(4)

Min EPS beat(4)

Max EPS beat(4)

EPS beat(8)

Avg EPS beat(8)

EPS beat(12)

Avg EPS beat(12)

EPS beat(16)

Avg EPS beat(16)

Revenue beat(2)

Avg Revenue beat(2)

Min Revenue beat(2)

Max Revenue beat(2)

Revenue beat(4)

Avg Revenue beat(4)

Min Revenue beat(4)

Max Revenue beat(4)

Revenue beat(8)

Avg Revenue beat(8)

Revenue beat(12)

Avg Revenue beat(12)

Revenue beat(16)

Avg Revenue beat(16)

PT rev (1m)

PT rev (3m)

EPS NQ rev (1m)

EPS NQ rev (3m)

EPS NY rev (1m)

EPS NY rev (3m)

Revenue NQ rev (1m)

Revenue NQ rev (3m)

Revenue NY rev (1m)

Revenue NY rev (3m)

Valuation

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A
P/S
P/FCF
P/OCF
P/B
P/tB
EV/EBITDA

EPS(TTM)

EPS(NY)

Fwd EY

FCF(TTM)

FCFY

OCF(TTM)

OCFY

SpS

BVpS

TBVpS

PEG (NY)N/A

PEG (5Y)N/A

Profitability

		Industry Rank	Sector Rank
ROA	-956.76%
ROE	N/A
ROCE
ROIC
ROICexc
ROICexgc
OM	N/A
PM (TTM)	N/A
GM	N/A
FCFM

ROA(3y)

ROA(5y)

ROE(3y)

ROE(5y)

ROIC(3y)

ROIC(5y)

ROICexc(3y)

ROICexc(5y)

ROICexgc(3y)

ROICexgc(5y)

ROCE(3y)

ROCE(5y)

ROICexcg growth 3Y

ROICexcg growth 5Y

ROICexc growth 3Y

ROICexc growth 5Y

OM growth 3Y

OM growth 5Y

PM growth 3Y

PM growth 5Y

GM growth 3Y

GM growth 5Y

F-Score

Asset Turnover3.47

Health

		Industry Rank	Sector Rank
Debt/Equity	N/A
Debt/FCF
Debt/EBITDA
Cap/Depr
Cap/Sales
Interest Coverage
Cash Conversion
Profit Quality
Current Ratio	0.65
Quick Ratio	0.48
Altman-Z

F-Score

WACC

ROIC/WACC

Cap/Depr(3y)

Cap/Depr(5y)

Cap/Sales(3y)

Cap/Sales(5y)

Profit Quality(3y)

Profit Quality(5y)

Growth

EPS 1Y (TTM)-2301.9%

EPS 3YN/A

EPS 5Y

EPS growth Q2Q

EPS Next Y79.88%

EPS Next 2Y

EPS Next 3Y

EPS Next 5Y

Revenue 1Y (TTM)53.58%

Revenue growth 3Y4.64%

Revenue growth 5Y

Revenue growth Q2Q

Revenue Next Year

Revenue Next 2Y

Revenue Next 3Y

Revenue Next 5Y

EBIT growth 1Y

EBIT growth 3Y

EBIT growth 5Y

EBIT Next Year

EBIT Next 3Y

EBIT Next 5Y

FCF growth 1Y

FCF growth 3Y

FCF growth 5Y

OCF growth 1Y

OCF growth 3Y

OCF growth 5Y

22ND CENTURY GROUP INC (XXII)

1. Profitability

1.1 Basic Checks

1.2 Ratios

1.3 Margins

More info and screens

2. Health

2.1 Basic Checks

2.2 Solvency

2.3 Liquidity

More info and screens

3. Growth

3.1 Past

3.2 Future

3.3 Evolution

More info and screens

4. Valuation

4.1 Price/Earnings Ratio

4.2 Price Multiples

4.3 Compensation for Growth

More info and screens

5. Dividend

5.1 Amount

More info and screens